Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND2 | P30279 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873025 | 0.76 | MAPK8 (0.33) | MAPK8RPS6KA3BCL6MAPK9MAPK10 | |
| SCHEMBL16048014 | 0.68 | CSF1R (0.47) | MAPK8BCL6MAPK9MAPK10KDR | |
| SCHEMBL16045208 | 0.68 | KDR (0.47) | MAPK8RPS6KA3BCL6MAPK9KCNH3 | |
| SCHEMBL21873002 | 0.66 | CYP3A4 (0.45) | KDRMAP4K4CSF1RRETFGFR1 | |
| SCHEMBL21873101 | 0.65 | MEN1 (0.38) | MAPK8RPS6KA3BCL6MAPK9KCNH3 | |
| SCHEMBL30467033 | 0.65 | BRAF (0.35) | MAPK8KDRLCKCSF1RPDGFRB | |
| SCHEMBL25913001 | 0.65 | BRAF (0.35) | MAPK8KDRLCKCSF1RPDGFRB | |
| SCHEMBL21872975 | 0.65 | CCNB2 (0.38) | KDRMAP4K4CSF1RRETGSK3B | |
| SCHEMBL4777940 | 0.63 | TRPM8 (0.42) | MAPK10KCNH3LMNAMAPTTRPM8 | |
| SCHEMBL16045601 | 0.60 | ALPL (0.33) | MAPK8BCL6KCNH3CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | MAPK8 1404/4885RPS6KA3 3981/4885BCL6 2252/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | MAPK8 1404/4885RPS6KA3 3981/4885BCL6 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.